109 related articles for article (PubMed ID: 29408272)
1. Prediction of DNA methylation in the promoter of gene suppressor tumor.
Saif I; Kasmi Y; Allali K; Ennaji MM
Gene; 2018 Apr; 651():166-173. PubMed ID: 29408272
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
3. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Esteller M
Oncogene; 2002 Aug; 21(35):5427-40. PubMed ID: 12154405
[TBL] [Abstract][Full Text] [Related]
4. Predicting aberrant CpG island methylation.
Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
[TBL] [Abstract][Full Text] [Related]
5. Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach.
Samy MD; Yavorski JM; Mauro JA; Blanck G
Cell Cycle; 2016 Jun; 15(12):1572-8. PubMed ID: 27074591
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
7. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
8. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
10. Differential methylation of CpG islands within the dermo1 gene promoter in several cancer cell lines.
Mao Y; Toh HB; Ding Z; Sun L; Hong L; Chen CS; Wu X
Oncol Rep; 2011 Jan; 25(1):107-11. PubMed ID: 21109964
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation and cancer.
Kulis M; Esteller M
Adv Genet; 2010; 70():27-56. PubMed ID: 20920744
[TBL] [Abstract][Full Text] [Related]
12. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation differences associated with tumor tissues identified by genome scanning analysis.
Liang G; Salem CE; Yu MC; Nguyen HD; Gonzales FA; Nguyen TT; Nichols PW; Jones PA
Genomics; 1998 Nov; 53(3):260-8. PubMed ID: 9799591
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
15. HMM-Fisher: identifying differential methylation using a hidden Markov model and Fisher's exact test.
Sun S; Yu X
Stat Appl Genet Mol Biol; 2016 Mar; 15(1):55-67. PubMed ID: 26854292
[TBL] [Abstract][Full Text] [Related]
16. Multi-omic analysis suggests tumor suppressor genes evolved specific promoter features to optimize cancer resistance.
Huang D; Wang X; Liu Y; Huang Z; Hu X; Hu W; Li Q; Chan H; Zou Y; Ho IHT; Wang Y; Cheng ASL; Kang W; To KF; Wang MHT; Wong SH; Yu J; Gin T; Zhang Q; Li Z; Shen J; Zhang L; Chan MTV; Liu X; Wu WKK
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33783485
[TBL] [Abstract][Full Text] [Related]
17. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
Ueki T; Walter KM; Skinner H; Jaffee E; Hruban RH; Goggins M
Oncogene; 2002 Mar; 21(13):2114-7. PubMed ID: 11960385
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and cancer.
Momparler RL; Bovenzi V
J Cell Physiol; 2000 May; 183(2):145-54. PubMed ID: 10737890
[TBL] [Abstract][Full Text] [Related]
19. Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating aberrant hypermethylation of promoter CpG islands in cancer cells.
Gao F; Ji G; Gao Z; Han X; Ye M; Yuan Z; Luo H; Huang X; Natarajan K; Wang J; Yang H; Zhang X
Genomics; 2014; 103(2-3):204-10. PubMed ID: 24407023
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing by DNA methylation in haematological malignancies.
Boultwood J; Wainscoat JS
Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
